AQST250516C10000
- 0.05
- 0.000.00%
Aquestive Therapeutics Newsroom
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
Aquestive Therapeutics Analyst Ratings
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
Buy Rating on Aquestive Therapeutics Driven by Anaphylm's Regulatory Progress and Strategic Launch Preparations
Aquestive Therapeutics Price Target Cut to $8.00/Share From $10.00 by Lake Street
Aquestive Therapeutics Analyst Ratings
Raymond James Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $7
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $8
Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)
A. G. P. Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $4.75
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Leerink Partners Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $13
Leerink Partners Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Announces Target Price $13
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
Promising Pipeline and Solid Financials: Analyst's Buy Rating on Aquestive Therapeutics
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10